Ana González Santis
Ana González Santis
Director Therapeutic Expertise Team Cardiometabolic
Ana Gonzalez-Santis, PhD, PMP, is a seasoned professional with a background in Molecular Biology and Biochemistry (Immunology). With 25+ years of experience in clinical research, she has demonstrated expertise in clinical operations and project management across various therapeutic areas. Her extensive involvement covers all phases of clinical trial development, including Real-World Evidence studies.
Currently serving as the Julius Clinical Cardiometabolic Therapeutic Expertise Team Director, Ana drives the creation and offer of effective and straightforward study delivery strategies to Julius Clinical’s Cardiometabolic clients. She oversees coordination among scientific officers, site networks, and business development teams to ensure effective trial execution. Her track record of successful project delivery and nuanced understanding of clinical trial requirements position her as an invaluable partner in the clinical research landscape.
Related
Julius Clinical appoints Stefan Timmerman as new Chief Financial Officer
Zeist, Netherlands, April 22, 2024 — We proudly welcome Stefan Timmerman as our new Chief Financial Officer (CFO), effective April 1st, following up Eelco Brouwer, who played a crucial role in the completion of the Ampersand transaction last yea...
Julius Clinical welcomes Ricard Quingles Blasi as new Chief Business Officer
Zeist, Netherlands, April 5, 2024 — We’re proud to announce the appointment of Ricard Quingles Blasi as our new Chief Business Officer (CBO). With over 25 years of dynamic leadership experience, Ricard Quingles Blasi brings a wealth of strate...
Upcoming webinar – Clinical consequences of the New MASLD Nomenclature
On the 27th of June, we will organise the webinar: 'Clinical Consequences of the New MASLD Nomenclature' with guest speaker Prof. Maja Thiele.During this webinar, our speaker and hosts will dive into the following topics:Is the MASLD nom...